PIP5K1A also exhibited negative correlations with these immune signatures and indicated a poor prognosis in BRCA, CESC, LIHC, PAAD, pheochromocytoma and paraganglioma (PCPG), prostate cancer (PRAD), rectum adenocarcinoma (READ), SKCM, testicular germ cell tumors (TGCT), and thyroid carcinoma (THCA). This evidence concerns the gene PIP5K1A and cervical squamous cell carcinoma.